Flailing MannKind makes a murky move to stay afloat, signing away pipeline drugs

Damian Garde

, decimated by the departure of former co-signer Sanofi, is trying to conserve value in the face of sluggish sales for its inhaled insulin, a deal to transfer some of its to an obscure new company.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS